Janux Therapeutics Inc. Common Stock JANX · Stock Open Janux Therapeutics Inc. Common Stock in new tab
Janux Therapeutics Inc. Common Stock Analysis (JANX)
Is Janux Therapeutics Inc. Common Stock a good investment? Janux Therapeutics Inc. Common Stock (JANX) is currently trading at 15.32 USD. Market analysts have a consensus price target of 37.19 USD. This suggests a potential upside from current levels.
Earnings Schedule: Janux Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -2.70.
Investor FAQ
Does Janux Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Janux Therapeutics Inc. Common Stock?
Janux Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.84.
Company Profile
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Community Discussion